Antidepressant may improve cognitive symptoms in people with HIV

February 25, 2016, Johns Hopkins University School of Medicine

In a small, placebo-controlled clinical trial, Johns Hopkins physicians report that the antidepressant paroxetine modestly improves decision-making and reaction time, and suppresses inflammation in people with HIV-associated cognitive impairment. The researchers say they believe this is the first time that a SSRI (selective serotonin reuptake inhibitor) has been shown to improve key measures of cognition in people with HIV in a controlled study.

The researchers note that many patients with HIV-associated neurocognitive disorders may already be benefiting cognitively by taking SSRIs in the dosages used in their study to treat depression, but the new study lends more rigorous scientific support to the drug's value.

The Johns Hopkins researchers are expected to present their findings Feb. 25 at the Conference on Retroviruses and Opportunistic Infections in Boston.

"Over a period of 20 years and after 10 clinical trials, this is the first time we've been able to clearly demonstrate benefit in a summary measure of cognitive performance for patients with HIV-associated neurocognitive disorders," says lead author Ned Sacktor, M.D., professor of neurology at the Johns Hopkins University School of Medicine.

HIV-associated neurocognitive disorders occur when infection with the virus that causes AIDS triggers nerve-damaging inflammation in the brain, leading to problems with learning, memory, decision-making and motor coordination. Up to 50 percent of people with HIV taking a cocktail of antiretroviral drugs are estimated to suffer from cognitive impairment, the researchers say.

In a search for a drug to safely blunt inflammation and reverse impairment, the investigators chose to test two drugs that looked promising based on earlier data published in 2014 by co-author Joseph Steiner, Ph.D., an adjunct associate professor of neurology.

Steiner had tested Food and Drug Administration-approved drugs paroxetine and the antifungal fluconazole, and showed that they protect neurons from death in laboratory cultures of rat nerve cells. Both drugs also cross the blood-brain barrier.

"There is a huge advantage to incorporating FDA-approved drugs into a clinical trial rather than developing whole new ones," says senior author Justin McArthur, M.B.B.S., M.P.H., professor and director of the Department of Neurology. "It's quicker, cheaper and very unlikely that there will be any surprises or any untoward side effects because the drug has been given to tens of thousands of people already."

The physicians enrolled 45 patients with HIV and cognitive impairment in a 24-week trial. Study participants couldn't have taken an SSRI within a month of the study's start. Participants received either 20 milligrams per day of paroxetine, 100 milligrams twice a day of fluconazole, the same doses of both paroxetine and fluconazole, or placebo drugs. In this study, both drugs were shown to be safe in combination with antiretroviral treatment regimens.

The team used eight neuropsychological tests to measure and evaluate psychomotor and motor speed performance and decision-making. The NPZ8 score, as it's called, comes from averaging the eight test results and evaluating this number using a statistical test that compares HIV positive patient to HIV negative scores. The numerical score represents the standard deviation from the mean. Patients given paroxetine alone or in combination with fluconazole improved their NPZ8 test scores by an average of 0.15. Those not taking paroxetine showed a deterioration of their score by -0.33 on this same measure of cognitive performance.

At the start of the trial and after 24 weeks of drug treatment, patients were also assessed on reaction times using the California Computerized Assessment Package (CalCAP) test, which asks participants to complete tasks like pressing a button when they see a number on the screen.

Patients taking paroxetine improved test scores on a subset of the CalCAP test by a 0.5 increase over the baseline measurement, but those not taking paroxetine showed essentially no improvement, with only a 0.06 change in score.

To learn if either or none of the drug treatments reduced levels of inflammatory proteins in the patients—a measure of inflammation—the physicians took blood samples from the patients at the start of the study and at 24 weeks after drug treatment. They measured the level of CD163, which is known to be higher than average in patients with HIV-associated neurocognitive disorders and an indicator of inflammation. Before treatment, patients with HIV had an average of 802 nanograms per milliliter of CD163 protein in the blood, but after treatment with paroxetine, the average level dropped to 738 nanograms per milliliter. Patients not given paroxetine saw their CD163 levels rise by an average of almost 400 nanograms per milliliter over the 24 weeks.

"By reducing inflammation, we hoped to have the added benefit of improving cognition, and our results show that to be the case," says Sacktor.

Because the team found no cognitive improvements with fluconazole alone, Sacktor says his work may now focus on larger studies using paroxetine alone.

Paroxetine treatment typically costs less than $15 a month. Some study participants reported side effects typical of SSRIs after taking paroxetine, including sexual dysfunction (three patients), headache (two patients), insomnia (two patients) or vivid dreams (two ). SSRI therapies for depression or anxiety don't always work for everyone, and people do discontinue using these drugs because of unwanted side effects.

Researchers do not yet know the precise mechanism by which an SSRI may improve .

Explore further: Antidepressant drug linked with increased risk of birth defects when taken in early pregnancy

Related Stories

Antidepressant drug linked with increased risk of birth defects when taken in early pregnancy

January 5, 2016
Using paroxetine—a medication prescribed to treat conditions including depression, obsessive-compulsive disorder, anxiety and posttraumatic stress disorder—during the first trimester of pregnancy may increase newborns' ...

Small study finds immunotherapy improves cognition in patients with schizophrenia

February 25, 2016
A recent study of a handful of patients supports mounting evidence that targeted suppression of inflammation packaged with standard therapy can improve the cognitive ability of patients with schizophrenia, physician-scientists ...

The impact of ketogenic diet on cognition in older adults with HIV

January 12, 2016
Poor cognitive function is a serious problem in the aging HIV-positive population, where it has been estimated that up to 59 percent of HIV-positive adults demonstrate at least mild cognitive impairment.

Paroxetine, an antidepressant drugs may provoke emotional disorders that persist after discontinuation

September 4, 2014
Three patients (two men and a woman) were referred to the Affective Disorders Program of the University of Bologna for paroxetine postwithdrawal symptoms. Patients were treated with paroxetine (from 20 to 60 mg/day) respectively ...

One drug used to prevent HIV transmission during pregnancy shows evidence of developmental effects

February 22, 2016
The antiretroviral (ARV) drug atazanavir—sometimes included in treatments to prevent mother-to-child HIV transmission during pregnancy—may have small but significant effects on infant development, reports a study in the ...

First non-hormonal remedy approved for menopausal hot flashes

July 1, 2013
(HealthDay)—Brisdelle (paroxetine) has been approved by the U.S. Food and Drug Administration as the first non-hormonal treatment to treat hot flashes associated with menopause.

Recommended for you

Roadmap reveals shortcut to recreate key HIV antibody for vaccines

December 11, 2018
HIV evades the body's immune defenses through a multitude of mutations, and antibodies produced by the host's immune system to fight HIV also follow convoluted evolutionary pathways that have been challenging to track.

Eliminating the latent reservoir of HIV

December 7, 2018
A new study suggests that a genetic switch that causes latent HIV inside cells to begin to replicate can be manipulated to completely eradicate the virus from the human body. Cells harboring latent HIV are "invisible" to ...

New research highlights why HIV-infected patients suffer higher rates of cancer

December 5, 2018
AIDS patients suffer higher rates of cancer because they have fewer T-cells in their bodies to fight disease. But new research examines why HIV-infected patients have higher rates of cancer—among the leading causes of death ...

Focus on resistance to HIV offers insight into how to fight the virus

November 30, 2018
Of the 40 million people around the world infected with HIV, less than one per cent have immune systems strong enough to suppress the virus for extended periods of time. These special immune systems are known as "elite controllers." ...

Patients with rare natural ability to suppress HIV shed light on potential functional cure

November 27, 2018
Researchers at Johns Hopkins have identified two patients with HIV whose immune cells behave differently than others with the virus and actually appear to help control viral load even years after infection. Moreover, both ...

Scientists unveil promising new HIV vaccine strategy

November 26, 2018
A new candidate HIV vaccine from Scripps Research surmounts technical hurdles that stymied previous vaccine efforts, and stimulates a powerful anti-HIV antibody response in animal tests.

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

not rated yet Feb 26, 2016
The main purpose of this antidepressant treatment of depression. Antidepressants are generally recommended as first-line therapy for the treatment of depression from mild to severe, when used in combination with talk therapy. Antidepressants can also be used to treat other disorders (anxiety, post-traumatic stress syndrome, panic disorder, social phobia). For more info please visit http://undepress....essants/

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.